Barinka Cyril, Byun Youngjoo, Dusich Crystal L, Banerjee Sangeeta R, Chen Ying, Castanares Mark, Kozikowski Alan P, Mease Ronnie C, Pomper Martin G, Lubkowski Jacek
Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA.
J Med Chem. 2008 Dec 25;51(24):7737-43. doi: 10.1021/jm800765e.
Urea-based, low molecular weight ligands of glutamate carboxypeptidase II (GCPII) have demonstrated efficacy in various models of neurological disorders and can serve as imaging agents for prostate cancer. To enhance further development of such compounds, we determined X-ray structures of four complexes between human GCPII and urea-based inhibitors at high resolution. All ligands demonstrate an invariant glutarate moiety within the S1' pocket of the enzyme. The ureido linkage between P1 and P1' inhibitor sites interacts with the active-site Zn(1)(2+) ion and the side chains of Tyr552 and His553. Interactions within the S1 pocket are defined primarily by a network of hydrogen bonds between the P1 carboxylate group of the inhibitors and the side chains of Arg534, Arg536, and Asn519. Importantly, we have identified a hydrophobic pocket accessory to the S1 site that can be exploited for structure-based design of novel GCPII inhibitors with increased lipophilicity.
基于尿素的谷氨酸羧肽酶II(GCPII)低分子量配体已在多种神经疾病模型中显示出疗效,并可作为前列腺癌的成像剂。为了进一步推动此类化合物的开发,我们高分辨率测定了人GCPII与基于尿素的抑制剂之间四种复合物的X射线结构。所有配体在酶的S1'口袋内均显示出不变的戊二酸部分。P1和P1'抑制剂位点之间的脲基连接与活性位点的Zn(1)(2+)离子以及Tyr552和His553的侧链相互作用。S1口袋内的相互作用主要由抑制剂的P1羧基与Arg534、Arg536和Asn519的侧链之间的氢键网络确定。重要的是,我们已鉴定出一个与S1位点相邻的疏水口袋,可用于基于结构设计具有更高亲脂性的新型GCPII抑制剂。